Triple Joy For European Biotechs As FDA OKs Byfavo
Acacia To Sell Rapid-Acting Sedative
Executive Summary
Having secured FDA approval, the UK's Acacia Pharma will market Byfavo, the first new product in the sedation space in decades, which was licensed from Italy's Cosmo and developed by Germany's Paion.
You may also be interested in...
RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Horizon Heralds Stellar Launch Of TED Drug Tepezza
Despite COVID-19, Horizon Therapeutics has pulled off a spectacularly successful launch of its thyroid eye disease therapy, Tepezza, thanks to pre-commercial activities that led to a high level of initial patient and prescriber awareness, and market access teams securing a decent reimbursement rate.
Doubts Over DBV's Future As US FDA Rejects Peanut Allergy Patch
The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.
Need a specific report? 1000+ reports available
Buy Reports